Geron Corporation’s Rytelo is now FDA approved for treating anemia caused by myelodysplastic syndromes. The new drug will compete against Reblozyl, a blockbuster Bristol Myers Squibb medicine.

The post Geron Drug Lands a First-in-Class FDA Approval in Type of Blood Cancer appeared first on MedCity News.

Servier drug Tibsovo is now approved for treating advanced cases of myelodysplastic syndrome that have an IDH1 mutation. It’s the first approval of a targeted therapy for this type of cancer.

The post Servier Gets First FDA Nod for Targeted Therapy in Rare Type of Blood Cancer appeared first on MedCity News.

Bristol Myers Squibb drug Reblozyl is now approved as a first-line therapy for anemia caused by myelodysplastic syndromes, a group of blood cancers. It’s the third indication for the drug, which analysts project could top $4 billion in peak sales.

The post BMS Cancer Drug’s New FDA Nod Puts It on Path to Reach Blockbuster Status appeared first on MedCity News.

An Eisai drug that produced disappointing data in a myelodysplastic syndrome study is getting another shot under a newly launched Roivant Sciences subsidiary, Hemavant. Roivant executives say the small molecule could be a safer, more effective alternative to MDS therapies marketed by Bristol Myers Squibb.

The post Roivant Sciences launches Hemavant to chase BMS in anemia from blood disease appeared first on MedCity News.

The companies said the FDA’s Oncologic Drugs Advisory Committee would review their application for Reblozyl in myelodysplastic syndrome. The drug, which won approval for a blood disorder last month, was developed under a partnership between Acceleron and Celgene, which BMS has since acquired.

The post BMS, Acceleron blood cancer drug to undergo FDA expert panel review appeared first on MedCity News.

The feasibility study was meant to see whether personalized cancer genetic sequencing and drug sensitivity recommendations could be done in a “clinically reasonable amount of time.”

The post Stanford, Notable Labs and Tempus collaborate on personalized medicine research for blood cancer appeared first on MedCity News.

Approval of luspatercept in myelodysplastic syndrome and beta-thalassemia is expected in April 2020, or as early as December of this year if it receives FDA priority review, an analyst wrote.

The post Celgene, Acceleron file for approval of blood disease drug luspatercept appeared first on MedCity News.